Literature DB >> 8612479

Characterization of ret oncogenic activation in MEN2 inherited cancer syndromes.

S Xing1, P A Smanik, M J Oglesbee, J E Trosko, E L Mazzaferri, S M Jhiang.   

Abstract

Germline mutations of c-ret, encoding a receptor-type tyrosine kinase, were found to be associated with variants of multiple endocrine neoplasia type 2 (MEN2A, MEN2B), and familial medullary thyroid carcinoma. NIH/3T3 stable transfectants expressing RET with a mutation of MEN2A (MEN2A/RET) or MEN2B (MEN2B/RET) gained a transformed morphology, formed colonies in soft agar, and formed tumors in nude mice. These results confirmed that both MEN2A/RET and MEN2B/RET exert dominant transforming activities in NIH/3T3 cells. However, in contrast to their clinical manifestation, transfectants expressing MEN2A/RET exhibited a higher tumorigenicity in nude mice than transfectants expressing MEN2B/RET may depend on the presence of its ligand and/or substrates that are absent in NIH/3T3 cells. No change in the cellular localization of the mutated RET proteins was observed compared to c-RET. Interestingly, ret activation in NIT/3T3 cells appeared to be associated with up-regulation of homologous gap-junctional intercellular communication and increased expression of a gap-junctional protein, connexin43.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8612479     DOI: 10.1210/endo.137.5.8612479

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  A novel functional genomics approach identifies mTERT as a suppressor of fibroblast transformation.

Authors:  Q X Li; J M Robbins; P J Welch; F Wong-Staal; J R Barber
Journal:  Nucleic Acids Res       Date:  2000-07-01       Impact factor: 16.971

2.  Calcium-induced activation of a mutant G-protein-coupled receptor causes in vitro transformation of NIH/3T3 cells.

Authors:  A O Hoff; G J Cote; H A Fritsche; H Qiu; P N Schultz; R F Gagel
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

Review 3.  Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis.

Authors:  J R Hansford; L M Mulligan
Journal:  J Med Genet       Date:  2000-11       Impact factor: 6.318

4.  Super-enhancer-controlled positive feedback loop BRD4/ERα-RET-ERα promotes ERα-positive breast cancer.

Authors:  Zao-Zao Zheng; Lin Xia; Guo-Sheng Hu; Jun-Yi Liu; Ya-Hong Hu; Yu-Jie Chen; Jia-Yin Peng; Wen-Juan Zhang; Wen Liu
Journal:  Nucleic Acids Res       Date:  2022-10-14       Impact factor: 19.160

5.  Expression of Ret/PTC1, -2, -3, -delta3 and -4 in German papillary thyroid carcinoma.

Authors:  B Mayr; E Pötter; P Goretzki; J Rüschoff; W Dietmaier; C Hoang-Vu; H Dralle; G Brabant
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

6.  Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type.

Authors:  S Uchino; S Noguchi; H Yamashita; M Sato; M Adachi; H Yamashita; S Watanabe; A Ohshima; S Mitsuyama; T Iwashita; M Takahashi
Journal:  Jpn J Cancer Res       Date:  1999-11

Review 7.  Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk.

Authors:  Kelly L Harris; Meagan B Myers; Karen L McKim; Rosalie K Elespuru; Barbara L Parsons
Journal:  Environ Mol Mutagen       Date:  2019-10-06       Impact factor: 3.216

Review 8.  Precision oncology for RET-related tumors.

Authors:  Antonella Verrienti; Giorgio Grani; Marialuisa Sponziello; Valeria Pecce; Giuseppe Damante; Cosimo Durante; Diego Russo; Sebastiano Filetti
Journal:  Front Oncol       Date:  2022-08-24       Impact factor: 5.738

9.  A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers.

Authors:  Daniel M Halperin; Alexandria T Phan; Ana O Hoff; Marie Aaron; James C Yao; Paulo M Hoff
Journal:  BMC Cancer       Date:  2014-08-02       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.